Barclays analyst Andrew Lazar maintains McCormick & Co (NYSE:MKC) with a Equal-Weight and lowers the price target from $94 to $82.
Acorda Therapeutics Q4 EPS $(0.57) Up From $(1.73) YoY, Sales $31.47M Down From $36.97M YoY
Acorda Therapeutics (NASDAQ:ACOR) reported quarterly losses of $(0.57) per share. This is a 67.05 percent increase over losses of $(1.73) per share from the same period last year. The company reported $31.47 million in
